Article
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
British journal of cancer - 14 Jul 2015
Jänne P A, Smith I, McWalter G, Mann H, Dougherty B, Walker J, Orr M C M, Hodgson D R, Shaw A T, Pereira J R, Jeannin G, Vansteenkiste J, Barrios C H, Franke F A, Crinò L, Smith P
Abstract excerpt
BACKGROUND: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825). METHODS: Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.